The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Alynlam Pharmaceuticals; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; Incyte; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO; Loxo
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Michael Rothe
No Relationships to Disclose
 
Pam K. Mangat
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
No Relationships to Disclose
 
Timothy Lewis Cannon
Honoraria - AstraZeneca; Bayer; Sirflex; Sirflex
Consulting or Advisory Role - Intermountain Healthcare
Other Relationship - Navican/ Intermountain Healthcare
 
Evthokia Hobbs
No Relationships to Disclose
 
Gregory Peter Kalemkerian
Consulting or Advisory Role - BioMed Valley Discoveries (I); Synlogic (I); Takeda (I)
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb Foundation (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck (Inst); Takeda (Inst)
 
Dominique C. Hinshaw
No Relationships to Disclose
 
Abby Gregory
Employment - Biohaven Pharmaceuticals (I); Pfizer (I)
Stock and Other Ownership Interests - Biohaven Pharmaceuticals (I)
 
Gina N. Grantham
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
Research Funding - Astellas Pharma (Inst)
 
Richard L. Schilsky
Leadership - Clarified Precision Medicine; Leap Therapeutics
Stock and Other Ownership Interests - EQRx; Leap Therapeutics
Honoraria - Toray Industries
Consulting or Advisory Role - AADi; Bryologyx; Cellworks; EQRx; Flatiron Health; Illumina; Scandion Oncology; Syapse; Zephyr AI
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); Taiho Oncology (Inst)